COVID-19: US Company, Novavax, Set to Commence Human Trials of 'Recombinant Vaccine' - THISDAYLIVE

  • 📰 THISDAY LIVE
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 51%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

COVID-19: US Company, Novavax, Set to Commence Human Trials of 'Recombinant Vaccine' via thisdaylive

An American biotechnology company, Novavax, is set to commence human trials of COVID-19 vaccine in Australia.

Novavax Research Chief, Dr Gregory Glenn, who spoke during a virtual press conference in Melbourne from Novavax’ headquarters in Maryland, US, said the firm had commenced the first phase of the trial in which 131 volunteers will be tested, adding that the volunteers will be from the cities of Melbourne and Brisbane and that the test will look for early signs of the vaccine’s effectiveness.

Many experimental vaccines are in early stages of testing or will begin testing across China, US, Europe. Vaccines are being created with different technologies, and work in different ways, which gives a possibility of at least one to succeed.

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 14. in JP

日本 最新ニュース, 日本 見出し